The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Sastravi 125mg/31.25mg/200mg Film-coated Tablets



Teva B.V.PA1986/120/004

Main Information

Trade NameSastravi 125mg/31.25mg/200mg Film-coated Tablets
Active SubstancesLevodopa
Carbidopa
Entacapone
Dosage FormFilm-coated tablet
Licence HolderTeva B.V.
Licence NumberPA1986/120/004

Group Information

ATC CodeN04BA Dopa and dopa derivatives
N04BA03 levodopa, decarboxylase inhibitor and COMT inhibitor

Status

License statusAuthorised
Licence Issued26/09/2014
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back